MARKET

RARE

RARE

Ultragenyx Pharm
NASDAQ
41.41
+0.86
+2.12%
After Hours: 41.41 0 0.00% 17:00 09/30 EDT
OPEN
40.66
PREV CLOSE
40.55
HIGH
43.00
LOW
40.66
VOLUME
902.96K
TURNOVER
0
52 WEEK HIGH
91.10
52 WEEK LOW
39.55
MARKET CAP
2.90B
P/E (TTM)
-5.6617
1D
5D
1M
3M
1Y
5Y
Ultragenyx to Participate at Citi BioPharma Conference
NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announ...
GlobeNewswire · 09/01 20:01
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
Gainers
Benzinga · 08/18 11:23
Cisco, Keysight Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Wolfspeed, Inc. (NYSE: WOLF) rose 20.7% to $103.40 in pre-market trading after the company reported better-than-expected Q4 results.
Benzinga · 08/18 10:07
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of n...
GlobeNewswire · 08/17 20:01
Ultragenyx Pharmaceutical's Return On Capital Employed Overview
Ultragenyx Pharmaceutical (NASDAQ:RARE) brought in sales totaling $89.34 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 3.84%, resulting in a loss of $158.16 million.
Benzinga · 08/05 14:25
Ultragenyx downgraded to in line at Evercore on 'noise' regarding Angelman candidate
Evercore ISI has downgraded Ultragenyx Pharmaceuticals (NASDAQ:RARE...
Seekingalpha · 08/01 16:09
Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2022
Upgrades
Benzinga · 08/01 14:22
--Evercore ISI Downgrades Ultragenyx Pharmaceutical to In-Line From Outperform, Adjusts Price Target to $60 From $95
--Evercore ISI Downgrades Ultragenyx Pharmaceutical to In-Line From Outperform, Adjusts Price Target to $60 From $95
MT Newswires · 08/01 05:40
More
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Webull offers kinds of Ultragenyx Pharmaceutical Inc stock information, including NASDAQ:RARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RARE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RARE stock methods without spending real money on the virtual paper trading platform.